Last reviewed · How we verify
NCT06070337
H-Guard Pilot Safety Evaluation in Haemodialysis Patients
NA trial testing H-Guard in Renal Failure in 8 participants. Completed in 29 February 2024.
29 February 2024
Quick facts
| Lead sponsor | Invizius Limited |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 8 |
| Start date | 19 October 2023 |
| Primary completion | 29 February 2024 |
| Estimated completion | 29 February 2024 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- H-Guard
Conditions studied
- Renal Failure — all drugs for Renal Failure →
- Renal Insufficiency — all drugs for Renal Insufficiency →
- Renal Disease — all drugs for Renal Disease →
Sponsor
Invizius Limited
Who can join
18 and older, any sex, with Renal Failure or Renal Insufficiency. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this research study is to find out the safety and effectiveness of a new medical device called H-Guard. During this research study, participants will receive the standard of care haemodialysis treatment, as decided by the treating doctor. Participants will be observed during 5-6 haemodialysis treatments throughout the course of the study. The only change to the treatment process, will be the use of the medical device (H-Guard) to prime the dialysis system, before one of the treatments. Participants will have various blood tests taken throughout the course of the study for safety and research analysis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06070337
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Renal Failure
Currently open trials in the same condition.
- NCT07293936 — Post-Filter Hematocrit · NA · recruiting
- NCT06814327 — Assessment of Organ Failure Risk Predictions in ICU · active not recruiting
- NCT06203977 — Inflammation REduction to Prevent cArdiovascular Injury in Renal Disease (REPAIR) · Phase 1 · recruiting
- NCT06142396 — Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure · EARLY_PHASE1 · recruiting
- NCT06620523 — Prevent Cardiac Surgery Associated AKI Trial · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06070337 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Invizius Limited
- Last refreshed: 7 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06070337.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing